MAXON
19.1.2021 16:52:50 CET | Business Wire | Press release
Today, Maxon announced it has completed the transaction to acquire the business segment of its Japanese distributor that services Maxon’s community and business concerns, and the formation of the first official office in Japan: Maxon Computer KK. For the last ten years, Maxon’s Japan Representative office in Tokyo, TMS Corp , has been well-known amongst the Maxon community. The establishment of Maxon Computer KK seeks to deepen this connection and show Maxon’s ongoing commitment to the Japanese market. Maxon have also announced that TMS Corp founder, Manfred Flick, has been appointed as the Regional Director of this new subsidiary. In addition, his entire motivated team will be part of the Maxon family.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210119005758/en/
TMS Corp specializes in the broadcast, industrial design, architectural design, event and exhibition, and game development industries in this region, within which Cinema 4D already has a strong established presence. Many major TV stations in Japan already rely on Cinema 4D in production, as do many design departments for notable industrial companies and this acquisition will therefore be welcome news for these companies.
“Japan has been and continues to be a huge growth area for Maxon,” says Maxon CEO, David McGavran. “The TMS team have been strong partners in the region. Their expertise will be invaluable in our efforts to grow the influence of our Redshift, Red Giant and Cinema 4D product lines in Japan and APAC.”
Benefits for Users
Through this acquisition Maxon aims to strengthen their support system and outreach for the large number of product users in the country, who will benefit from Maxon’s ongoing provision of regular free seminars. Moreover, the inclusion of Red Giant and Redshift products, as well as the full Maxon One bundle, will certainly provide many more exciting tools for creatives to explore.
About Manfred Flick, Regional Director of Maxon KK
In 1994, Manfred founded TMS Corp. in Tokyo after having worked eight years in Japan as a broadcast engineer for a German company. A visit to the Siggraph trade show in 1998 in Los Angeles led him to the Maxon booth where he witnessed the popularity and potential of Cinema 4D for the first time. This kicked off an invaluable more than two-decade long relationship which has opened the door to Japan for Maxon. For TMS it was an exciting challenge to introduce a new product into a competitive market. Through tenacity, patience and enthusiasm Manfred and his experienced team, Cinema 4D has quickly become an essential tool in all design industries, and Maxon’s Red Giant and Redshift product lines are quickly gaining that same popularity.
About Maxon
Maxon makes powerful, yet approachable software solutions for content creators working in 2D and 3D design, motion graphics, visual effects and visualization. Maxon’s innovative product portfolio helps artists supercharge their creative workflows. Its product lines include the award-winning Cinema 4D suite of 3D modeling, simulation and animation technology, the diverse Red Giant lineup of revolutionary editing, motion design and filmmaking tools, and the high-end production, blazingly fast Redshift rendering solutions.
Maxon’s team is comprised of fun, passionate people who believe in building and empowering a successful artistic community. From its popular, inclusive events to its free Cineversity educational resources, Maxon recognizes that developing strong connections with creatives and fostering their professional growth is integral to Maxon’s ability to stay on top of industry trends and better serve customers.
Maxon is part of the Nemetschek Group.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210119005758/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Duco Launches the First Agentic Operations Platform for Financial Services27.5.2026 09:20:00 CEST | Press release
Duco, today launched the first agentic Operations platform for financial services. Built on the engine that already processes 20 billion transactions every month for more than 200 clients, including seven of the top 20 banks and ten of the top 20 asset managers, the platform brings together everything firms need to run post-trade Operations alongside autonomous agents, safely and at scale. The launch establishes a breakthrough the industry has been waiting for. A tool surface, purpose-built for agents. Duco has unbundled its platform into a new alternative agent layer that reconfigures its platform into hundreds of discrete capabilities servicing post trade. Model Context Protocol (MCP) gives capabilities covering reconciliation, data preparation, data access, audit trails, exception management, document creation and more. For the first time, agents have a verified, deterministic toolset built specifically for post-trade. Agents do not replace matching, rules or audit; they use them. P
Brenus Pharma Announces FDA Acceptance of IND Application for STC-1010 (BreAK-CRC001) in MSS Metastatic Colorectal Cancer (mCRC)27.5.2026 08:49:00 CEST | Press release
STC-1010 is a first-in-class allogeneic in vivo immunotherapy for which the FDA has authorized clinical evaluation in the U.S. under the BreAK-CRC001 study. This strategic milestone enables the company to execute a global clinical strategy following European regulatory approvals (ANSM, AFMPS), first patients dosed with preliminary results and good tolerability observed in early Phase Ia. First data are expected to be presented during ESMO annual congress 2026. Brenus Pharma, a clinical stage biotechnology company developing novel in vivo immunotherapies for solid tumors, announced that the U.S. Food and Drug Administration (FDA) has accept the company's Investigational New Drug (IND) application for its first drug candidate, STC-1010, in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). STC-1010 is designed to address a critical unmet need worldwide. Approximately 95% of mCRC patients have MSS tumors, which demonstrate minimal response to standard immunotherapies. The FD
Tide Crosses 2 Million Members Worldwide - Big Step Forward in Mission to Support and Grow Small Businesses27.5.2026 08:00:00 CEST | Press release
Continuing to grow in the UK and internationally, with India seeing especially strong member growth in the last 12 months In the UK, Tide has 15% market share and has helped small businesses access over £1.75bn in credit Rapid roll out of products; from admin, accounting and tax tools; subscription options; payment solutions; government registrations; bill payments and credit Tide, the UK’s leading business management platform, today announces it has crossed 2 million members globally, with India in particular seeing strong growth. More than 1.1 million small businesses joined Tide in India since the company launched there in December 2022. This makes India Tide’s fastest-growing market by member acquisition. The UK is Tide’s home market, with 900,000 SMEs, 15% market share, and the majority of the company’s revenue. Tide’s steadily expanding its presence in Europe, with Germany and France, where the platform is gaining strong traction, thanks to millions of small businesses turning to
Alfasigma presents first data on filgotinib from the Phase 3 OLINGUITO trial in axial spondyloarthritis at EULAR 202627.5.2026 08:00:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific and investor media only.In the OLINGUITO Phase 3 study in radiographic (r) and non-radiographic (nr) axial spondyloarthritis (axSpA) a significantly greater proportion of patients achieved the prespecified primary endpoint of ASAS40 with filgotinib compared with placebo at week 16.The improvements in signs and symptoms of axSpA with filgotinib, an oral, once-daily JAK1 preferential inhibitor, were observed as early as week 1 and maintained over 52 weeks of treatment.In the r-axSpA and nr-axSpA filgotinib groups, of those achieving a response in the prespecified primary endpoint of ASAS40 at week 16, 84.6% and 78.0% maintained their responses to week 52, respectively.In OLINGUITO no new safety signals were observedfor filgotinib over 52 weeks, and the safety profile was consistent with the known overall safety profile.Primary results from the Phase 3 OLINGUITO tria
Royal London Asset Management Expands Relationship with SS&C to Service New Australian Funds27.5.2026 00:00:00 CEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that Royal London Asset Management, a leading U.K. fund management company, has extended its relationship with SS&C. SS&C Global Investor & Distribution Solutions will provide fund administration and unit registry services for its new range of Australian active funds, including: Royal London Global Equity Diversified Fund Royal London Global Equity Enhanced Fund Royal London Global Equity Select Fund Royal London Short Duration Global High Yield Bond Fund RLAM is part of Royal London, the U.K.’s largest mutual life, pensions and investment company. SS&C services approximately £72bn in assets under management across its U.K. fund range. Equity Trustees will serve as the Responsible Entity for RLAM’s new funds, which have launched with around AUD $1 billion in AUM. The unit trusts are structured as feeder funds, providing investors with indirect exposure to RLAM’s range of Dublin-domiciled Undertakings for Collective Investm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom